mProX™ Human MELTF Stable Cell Line

Product Information

Target Family

Other Targets

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;A549;PC-9

Target Classification

Other Targets Drug Discovery Assays and Products

Target Research Area

Cancer Research

Related Diseases

Osteogenic Sarcoma; Melanoma

Gene ID

Human:4241

UniProt ID

Human:P08582

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

MELTF, an oncogene, has been found to play a role in the progression of lung adenocarcinoma (LUAD) by regulating the Notch signaling pathway. It has been shown to foster the malignant progression of LUAD cells and promote the expression of NOTCH1 and HES1 proteins. MELTF has also been identified as a novel gene signature for LUAD, which can be used to predict immunotherapy and prognosis. In addition, MELTF is involved in the GPI-anchoring pathway and is targeted by human cytomegalovirus (HCMV). Furthermore, SGN-CD228A, an investigational antibody-drug conjugate, targets MELTF and has shown potent antitumor activity in various solid tumor models. Lastly, MELTF has been implicated in the regulation of ferroptosis, pyroptosis, and autophagy in platelet-rich plasma-mediated endometrial epithelium regeneration. Overall, MELTF has emerged as a potential target for treating LUAD and other diseases.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human MELTF Stable Cell Line (S01YF-1023-PY278). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Taylor Williams (Verified Customer)

What is the role of MELTF in cancer progression? Jan 13 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

MELTF-AS1, a long non-coding RNA, is associated with the progression of non-small cell lung cancer, indicating its potential as a prognostic biomarker. Jan 13 2020

chat Taylor Brown (Verified Customer)

How does MELTF influence endometrial epithelium regeneration? Feb 06 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

MELTF may regulate endometrium regeneration by up-regulating pathways related to retinol metabolism and extracellular matrix interaction, suggesting its role in tissue regeneration. Feb 06 2022

Published Data

Fig.1 MELTF promotes the proliferation of LUAD cells.

In the colony formation assay, it was observed that a significant decrease in cell proliferation of A549 cells was brought about by the knockdown of MELTF, whereas a notable acceleration in the proliferation capacity of PC-9 cells was achieved through the overexpression of MELTF.

Ref: Zhang, Lidan, and Lei Shi. "The E2F1/MELTF axis fosters the progression of lung adenocarcinoma by regulating the Notch signaling pathway." Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 827 (2023): 111837.

Pubmed: 37820570

DOI: 10.1016/j.mrfmmm.2023.111837

Research Highlights

Zhang, Lidan; S, Lei. "The E2F1/MELTF axis fosters the progression of lung adenocarcinoma by regulating the Notch signaling pathway." Mutation research, 2023.
In the field of medicine, lung adenocarcinoma (LUAD) is recognized as the most common form of lung cancer. The oncogene MELTF has been observed to have elevated levels of expression in multiple types of cancer tissues. Despite this, the specific impact of MELTF on the advancement of LUAD is not fully understood. This study aims to analyze the influence of MELTF on LUAD progression and elucidate its underlying mechanism.
Zhang, Lidan; S, Lei. "The E2F1/MELTF axis fosters the progression of lung adenocarcinoma by regulating the Notch signaling pathway." Mutation research, 2023.
Pubmed: 37820570 DOI: 10.1016/j.mrfmmm.2023.111837

Shu, Jianfeng. et al. "Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis." Frontiers in immunology, 2023.
The study focuses on lung adenocarcinoma (LUAD), which is a prevalent form of lung cancer and has a 5-year overall survival rate of less than 20% in individuals with advanced disease. Its goal is to develop a risk model for improved guidance of immunotherapy in LUAD patients. This research aims to increase the effectiveness of immunotherapy and ultimately improve the outcomes of LUAD patients.
Shu, Jianfeng. et al. "Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis." Frontiers in immunology, 2023.
Pubmed: 37583701 DOI: 10.3389/fimmu.2023.1177847